Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05856760 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

A Phase 2 study of Immunoglobulin A Nephropathy, sponsored by Travere Therapeutics.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
20
Study locations

NCT05856760 is a Phase 2 study of Immunoglobulin A Nephropathy that has completed, run by Travere Therapeutics. The registered enrollment target is 48 participants, below the 301-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05856760, a Phase 2 study of Immunoglobulin A Nephropathy, has completed, sponsored by Travere Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
20
Study locations

Study Summary

This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry

Conditions Studied

Immunoglobulin A Nephropathy

Interventions

  • DRUG Sparsentan

Study Locations (20)

California

  • Travere Investigational Site - Chula Vista
  • Travere Investigational Site - Garden Grove
  • Travere Investigational Site - Glendale

Idaho

  • Travere Investigational Site - Boise
  • Travere Investigational Site - Chubbuck
  • Travere Investigational Site - Idaho Falls

New York

  • Travere Investigation Site - Clifton Park
  • Travere Investigational Site - Fresh Meadows
  • Travere Investigational Site - New York

Illinois

  • Travere Investigational Site - Chicago
  • Travere Investigational Site - Evergreen Park

North Carolina

  • Travere Investigational Site - Jacksonville
  • Travere Investigational Site - New Bern

Alabama

  • Travere Investigational Site - Birmingham

Colorado

  • Travere Investigational Site - Denver

Indiana

  • Travere Investigational Site - Fort Wayne

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2023-05-19
Est. Completion 2024-10-25
Phase Phase 2

Sponsor

Travere Therapeutics

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05856760

The ClinicalTrials.gov registry entry for NCT05856760 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 301-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (84% lower). The listed sponsor is Travere Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which Sparsentan is the first listed.

NCT05856760 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Idaho, New York.

Frequently Asked Questions

What is clinical trial NCT05856760 about?

NCT05856760 is a clinical study titled "A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN". This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 wee...

What is the current status of trial NCT05856760?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2023-05-19. Estimated completion is 2024-10-25.

What conditions does trial NCT05856760 study?

This clinical trial studies the following conditions: Immunoglobulin A Nephropathy.

What interventions are being tested in trial NCT05856760?

The interventions under investigation include: Sparsentan (DRUG).

Who is sponsoring clinical trial NCT05856760?

This trial is sponsored by Travere Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05856760 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Immunoglobulin A Nephropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Immunoglobulin A Nephropathy

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.